Cargando…
Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series
BACKGROUND: Defects of the primary cilium and its anchoring structure, the basal body, cause a number of human genetic disorders, collectively termed ciliopathies: primary ciliary dyskinesia, Bardet-Biedl syndrome, polycystic kidney and liver disease, nephronophthisis, Alström syndrome, Meckel-Grube...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648950/ https://www.ncbi.nlm.nih.gov/pubmed/19128470 http://dx.doi.org/10.1186/1757-1626-2-19 |
_version_ | 1782164999024672768 |
---|---|
author | Mihai, Cristina Maria Catrinoiu, Doina Toringhibel, Marius Stoicescu, Ramona Mihaela Ticuta, Negreanu-Pirjol Anca, Hancu |
author_facet | Mihai, Cristina Maria Catrinoiu, Doina Toringhibel, Marius Stoicescu, Ramona Mihaela Ticuta, Negreanu-Pirjol Anca, Hancu |
author_sort | Mihai, Cristina Maria |
collection | PubMed |
description | BACKGROUND: Defects of the primary cilium and its anchoring structure, the basal body, cause a number of human genetic disorders, collectively termed ciliopathies: primary ciliary dyskinesia, Bardet-Biedl syndrome, polycystic kidney and liver disease, nephronophthisis, Alström syndrome, Meckel-Gruber syndrome and some forms of retinal degeneration. Alström syndrome is an extremely rare, autosomal recessive genetic disorder characterized by a group of signs and symptoms including infantile onset dilated cardiomyopathy, blindness, hearing impairment/loss, obesity, diabetes, hepatic and renal dysfunction. Because adult growth hormone deficiency and Alström Syndrome share some clinical and metabolic features, we studied the GH-IGF1 axis, using MRI techniques and dynamic tests in 3 unrelated patients with Alström syndrome. CASE PRESENTATION: The patients were hospitalized and the growth hormone stimulatory tests were made, as well as brain MRI. Insulin provocative test revealed a severe GH deficiency in these patients, defined by a peak response to insulin-induced hypoglycemia less than 3 ng/dl and IGF1 concentrations less than – 2SDS. We didn't find multiple pituitary hormone deficiency and we noticed only a severe GH deficiency in all three patients. The MRI study of the diencephalic and pituitary region was suggestive for the diagnosis of empty sella in one patient. One patient received Recombinant-GH replacement for one year with very good results, one underwent a gastric sleeve with a satisfactory outcome, one patient died due to the progression of the cardiac myopathy. CONCLUSION: Future studies are needed to assses if the substitution therapy with Recombinant Growth hormone is cost-effective and without risk in such patients with Alström Syndrome and severe insulin resistance, despite our good results in one patient. Also, careful clinical and genetic studies can contribute to a better understanding of the evolution after different therapeutical attempt in the complex disorders such as Alström Syndrome. |
format | Text |
id | pubmed-2648950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26489502009-02-28 Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series Mihai, Cristina Maria Catrinoiu, Doina Toringhibel, Marius Stoicescu, Ramona Mihaela Ticuta, Negreanu-Pirjol Anca, Hancu Cases J Case Report BACKGROUND: Defects of the primary cilium and its anchoring structure, the basal body, cause a number of human genetic disorders, collectively termed ciliopathies: primary ciliary dyskinesia, Bardet-Biedl syndrome, polycystic kidney and liver disease, nephronophthisis, Alström syndrome, Meckel-Gruber syndrome and some forms of retinal degeneration. Alström syndrome is an extremely rare, autosomal recessive genetic disorder characterized by a group of signs and symptoms including infantile onset dilated cardiomyopathy, blindness, hearing impairment/loss, obesity, diabetes, hepatic and renal dysfunction. Because adult growth hormone deficiency and Alström Syndrome share some clinical and metabolic features, we studied the GH-IGF1 axis, using MRI techniques and dynamic tests in 3 unrelated patients with Alström syndrome. CASE PRESENTATION: The patients were hospitalized and the growth hormone stimulatory tests were made, as well as brain MRI. Insulin provocative test revealed a severe GH deficiency in these patients, defined by a peak response to insulin-induced hypoglycemia less than 3 ng/dl and IGF1 concentrations less than – 2SDS. We didn't find multiple pituitary hormone deficiency and we noticed only a severe GH deficiency in all three patients. The MRI study of the diencephalic and pituitary region was suggestive for the diagnosis of empty sella in one patient. One patient received Recombinant-GH replacement for one year with very good results, one underwent a gastric sleeve with a satisfactory outcome, one patient died due to the progression of the cardiac myopathy. CONCLUSION: Future studies are needed to assses if the substitution therapy with Recombinant Growth hormone is cost-effective and without risk in such patients with Alström Syndrome and severe insulin resistance, despite our good results in one patient. Also, careful clinical and genetic studies can contribute to a better understanding of the evolution after different therapeutical attempt in the complex disorders such as Alström Syndrome. BioMed Central 2009-01-07 /pmc/articles/PMC2648950/ /pubmed/19128470 http://dx.doi.org/10.1186/1757-1626-2-19 Text en Copyright ©2009 Mihai et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Mihai, Cristina Maria Catrinoiu, Doina Toringhibel, Marius Stoicescu, Ramona Mihaela Ticuta, Negreanu-Pirjol Anca, Hancu Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series |
title | Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series |
title_full | Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series |
title_fullStr | Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series |
title_full_unstemmed | Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series |
title_short | Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series |
title_sort | impaired igf1-gh axis and new therapeutic options in alström syndrome patients: a case series |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648950/ https://www.ncbi.nlm.nih.gov/pubmed/19128470 http://dx.doi.org/10.1186/1757-1626-2-19 |
work_keys_str_mv | AT mihaicristinamaria impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries AT catrinoiudoina impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries AT toringhibelmarius impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries AT stoicescuramonamihaela impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries AT ticutanegreanupirjol impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries AT ancahancu impairedigf1ghaxisandnewtherapeuticoptionsinalstromsyndromepatientsacaseseries |